New treatment options for generalized HER2-positive breast cancer in higher-line systemic palliative therapy
{{output}}
Background: HER2-positive breast cancer occurs in about 15-20 % of all breast cancers. It is both a prognostic and predictive biomarker and the introduction of anti-HER2 therapy over the last 20 years has significantly improved o... ...
